Published online before print August 5, 2002, doi: 10.1161/01.CIR.0000029091.61707.6B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:905.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Smoking Is Associated With Altered Endothelial-Derived Fibrinolytic and Antithrombotic Factors
An In Vitro Demonstration
From Saint Vincent Catholic Medical Centers of New York (R.S.B., J.A.A., D.C.S.), New York, NY, and The School of Biomedical and Life Sciences (R.S.B., L.-J.R.), University of Surrey, UK.
Correspondence to John A. Ambrose, MD, The Comprehensive Cardiovascular Center, Department of Medicine, Saint Vincent Catholic Medical Centers of New York, 170 West 12th St, New York, NY 10011. E-mail jambrose{at}saintvincentsnyc.org
Background— Data about the effects of smoking on thrombo-hemostatic factors (tissue factor [TF] and tissue factor pathway inhibitor [TFPI-1]) are limited and on fibrinolytic factors (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1 [PAI-1]) are debatable. The present study investigated the smoking-related, endothelial cell (EC)–specific responses for these factors and their relation to nitric oxide (NO) production in vitro.
Methods and Results— Serum from 8 nonsmokers and 15 smokers were incubated with confluent (
85%) human umbilical vein endothelial cells (HUVECs) in 24-well tissue-culture plates for 12 hours. After the incubation, basal NO, t-PA, PAI-1, TF, TFPI-1 production, and substance P (SP)–stimulated NO, t-PA, and PAI-1 production were determined. HUVECs treated with smokers’ serum showed lower basal (P<0.02) and SP-stimulated (P=0.059) t-PA production but similar basal and stimulated PAI-1 production (P=0.9 and P=0.6) compared with nonsmokers. Basal t-PA/PAI-1 molar ratio was significantly reduced in smokers (P<0.005). TFPI-1 level in the cell culture supernatant was also significantly lower in smokers compared with the nonsmoker group (P<0.05) with no difference in TF level between both groups (P=0.5). As previously reported, both basal (P<0.001) and SP-stimulated (P<0.05) NO production were significantly reduced in smokers. Basal TFPI-1 in culture correlated positively with basal NO production (r=0.42, P=0.04) and negatively with serum cotinine level (r=-0.6, P=0.01).
Conclusions— These results indicate that cigarette smoking is associated with alterations in EC-derived fibrinolytic (t-PA) and antithrombotic (TFPI-1) factors. To our knowledge, this is the first demonstration that EC-derived TFPI is affected by smoking and endogenous NO or that the degree of smoke exposure may influence TFPI levels in an EC milieu.
Key Words: smoking • thrombosis • fibrinolysis • nitric oxide
This article has been cited by other articles:
 |
|
 |
|
  S. Shetty, P. Shetty, S. Idell, T. Velusamy, Y. P. Bhandary, and R. S. Shetty Regulation of Plasminogen Activator Inhibitor-1 Expression by Tumor Suppressor Protein p53 J. Biol. Chem., July 11, 2008; 283(28): 19570 - 19580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, C. Iribarren, M. Chandra, P. V. Lathon, S. P. Fortmann, T. Quertermous, M. A. Hlatky, and for the Atherosclerotic Disease, Vascular Function Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med, February 21, 2006; 144(4): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Oliver, D. J. Webb, and D. E. Newby Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Wannamethee, G. D.O. Lowe, A. G. Shaper, A. Rumley, L. Lennon, and P. H. Whincup Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease Eur. Heart J., September 1, 2005; 26(17): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hermann, H. Krum, and F. Ruschitzka To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk Circulation, August 16, 2005; 112(7): 941 - 945. [Full Text] [PDF]
|
|
|
|
 |
|
 V. F. Tapson The Role of Smoking in Coagulation and Thromboembolism in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Johnson, L. Mureebe, and D. Silver Hypercoagulable States: A Review Vascular and Endovascular Surgery, March 1, 2005; 39(2): 123 - 133. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Ruel, R. G. Masters, F. D. Rubens, P. J. Bedard, A. L. Pipe, W. G. Goldstein, P. J. Hendry, and T. G. Mesana Late incidence and determinants of stroke after aortic and mitral valve replacement Ann. Thorac. Surg., July 1, 2004; 78(1): 77 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ambrose and R. S. Barua The pathophysiology of cigarette smoking and cardiovascular disease: An update J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1731 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsiara, M. Elisaf, and D. P. Mikhailidis Influence of Smoking on Predictors of Vascular Disease Angiology, September 1, 2003; 54(5): 507 - 530. [Abstract] [PDF]
|
|
|
|
 |
|
 F. L Ruberg and J. Loscalzo Prothrombotic determinants of coronary atherothrombosis Vascular Medicine, November 1, 2002; 7(4): 289 - 299. [Abstract] [PDF]
|
|